Physician profile
Jeffrey Ray
NPI 1013013556
$907.74
in general payments reported to CMS, 2019-2025
15 companies · $295 in 2025
The $295 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.67 · 2021: $29.79 · 2022: $31.37 · 2023: $169 · 2024: $367 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $830.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $262.85 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Dexcom, INC. | $158.20 | 2023-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $100.62 | 2023-2024 | Zepbound, Mounjaro, Jardiance |
| Astellas Pharma US INC | $86.69 | 2022-2024 | Veozah, Myrbetriq |
| Jazz Pharmaceuticals INC. | $54.36 | 2024-2025 | |
| Abbott Laboratories | $49.45 | 2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $45.81 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $27.38 | 2023 | Livalo, Seglentis |
| E.R. Squibb & Sons, L.L.C. | $22.53 | 2024 | Eliquis |
| Sumitomo Pharma America, INC. | $20.00 | 2024 | Gemtesa |
| Pfizer INC. | $17.14 | 2024 | |
| Amgen INC. | $16.31 | 2025 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $16.10 | 2023 | |
| Csl Behring | $15.67 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.63 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.